The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future.
Brian Godman,Brian Godman,Brian Godman,Mainul Haque,Trudy Leong,Eleonora Allocati,Santosh Kumar,Salequl Islam,Jaykaran Charan,Farhana Akter,Amanj Kurdi,Amanj Kurdi,Amanj Kurdi,Carlos Vassalo,Muhammed Abu Bakar,Sagir Abdur Rahim,Nusrat Sultana,Farzana Deeba,M. A. Halim Khan,A. B.M.Muksudul Alam,Iffat Jahan,Zubair Mahmood Kamal,Humaira Hasin,Munzur-E-Murshid,Shamsun Nahar,M. E. Haque,Siddhartha Dutta,Jha Pallavi Abhayanand,Rimple Jeet Kaur,Godfrey Mutashambara Rwegerera,Renata Cristina Rezende Macedo do Nascimento,Isabella Piassi Godói,Mohammed Irfan,Adefolarin A. Amu,Patrick Matowa,Joseph Acolatse,Robert Incoom,Israel Abebrese Sefah,Jitendra Acharya,Sylvia Opanga,Lisper Wangeci Njeri,David Kimonge,Hye Young Kwon,Seung Jin Bae,Karen Koh Pek Khuan,Abdullahi Rabiu Abubakar,Ibrahim Haruna Sani,Tanveer Ahmed Khan,Shahzad Hussain,Zikria Saleem,Oliver Ombeva Malande,Thereza Piloya-Were,Rosana Gambogi,Carla Hernandez Ortiz,Luke Alutuli,Aubrey Chichonyi Kalungia,Iris Hoxha,Vanda Marković-Peković,Biljana Tubić,Guenka Petrova,Konstantin Tachkov,Ott Laius,András Harsányi,András Inotai,Arianit Jakupi,Svens Henkuzens,Kristina Garuoliene,Jolanta Gulbinovič,Magdalene Wladysiuk,Jakub Rutkowski,Ileana Mardare,Jurij Fürst,Stuart McTaggart,Sean MacBride-Stewart,Caridad Pontes,Caridad Pontes,Corinne Zara,Eunice Twumwaa Tagoe,Rita Banzi,Janney Wale,Mihajlo Jakovljevic,Mihajlo Jakovljevic +81 more
TLDR
In this paper, the authors assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of insulin analogue biosimilars to benefit all key stakeholders.Abstract:
Background: Diabetes mellitus rates continue to rise, which coupled with increasing costs of associated complications has appreciably increased global expenditure in recent years. The risk of complications are enhanced by poor glycaemic control including hypoglycaemia. Long-acting insulin analogues were developed to reduce hypoglycaemia and improve adherence. Their considerably higher costs though have impacted their funding and use. Biosimilars can help reduce medicine costs. However, their introduction has been affected by a number of factors. These include the originator company dropping its price as well as promoting patented higher strength 300 IU/ml insulin glargine. There can also be concerns with different devices between the manufacturers. Objective: To assess current utilisation rates for insulins, especially long-acting insulin analogues, and the rationale for patterns seen, across multiple countries to inform strategies to enhance future utilisation of long-acting insulin analogue biosimilars to benefit all key stakeholders. Our approach: Multiple approaches including assessing the utilisation, expenditure and prices of insulins, including biosimilar insulin glargine, across multiple continents and countries. Results: There was considerable variation in the use of long-acting insulin analogues as a percentage of all insulins prescribed and dispensed across countries and continents. This ranged from limited use of long-acting insulin analogues among African countries compared to routine funding and use across Europe in view of their perceived benefits. Increasing use was also seen among Asian countries including Bangladesh and India for similar reasons. However, concerns with costs and value limited their use across Africa, Brazil and Pakistan. There was though limited use of biosimilar insulin glargine 100 IU/ml compared with other recent biosimilars especially among European countries and Korea. This was principally driven by small price differences in reality between the originator and biosimilars coupled with increasing use of the patented 300 IU/ml formulation. A number of activities were identified to enhance future biosimilar use. These included only reimbursing biosimilar long-acting insulin analogues, introducing prescribing targets and increasing competition among manufacturers including stimulating local production. Conclusions: There are concerns with the availability and use of insulin glargine biosimilars despite lower costs. This can be addressed by multiple activities.read more
Citations
More filters
Journal ArticleDOI
Current utilization patterns for long-acting insulin analogues including biosimilars among selected Asian countries and the implications for the future.
Brian Godman,Brian Godman,Brian Godman,Mainul Haque,Santosh Kumar,Salequl Islam,Jaykaran Charan,Farhana Akter,Amanj Kurdi,Amanj Kurdi,Amanj Kurdi,Eleonora Allocati,Muhammed Abu Bakar,Sagir Abdur Rahim,N Sultana,Farzana Deeba,M. A. Halim Khan,A. B.M.Muksudul Alam,Iffat Jahan,Zubair Mahmood Kamal,Humaira Hasin,Munzur-E-Murshid,Shamsun Nahar,M. E. Haque,Siddhartha Dutta,Jha Pallavi Abhayanand,Rimple Jeet Kaur,Jitendra Acharya,Takuma Sugahara,Hye Young Kwon,Seung Jin Bae,Karen Koh Pek Khuan,Tanveer A. Khan,Shahzad Hussain,Zikria Saleem,Alice Pisana,Janney Wale,Mihajlo Jakovljevic,Mihajlo Jakovljevic +38 more
TL;DR: In this article, the authors report that prevalence rates for diabetes mellitus continue to rise, which, coupled with increasing costs of complications, has appreciably increased expenditure in recent years.
Journal ArticleDOI
Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries
Alice Pisana,Björn Wettermark,Amanj Kurdi,Biljana Tubić,Caridad Pontes,Corinne Zara,Eric Van Ganse,Guenka Petrova,Ileana Mardare,Jurij Fürst,Marta Roig-Izquierdo,O. Melien,Patricia Vella Bonanno,Rita Banzi,Vanda Marković Peković,Zornitsa Mitkova,Brian Godman +16 more
TL;DR: The types of available datasets for collecting patient-level data for oncology among different European countries are outlined to highlight concerns regarding the use and availability of such data from a health authority perspective as well as possibilities for cross-national collaboration to improve data collection and inform decision-making.
Journal ArticleDOI
A pilot study regarding the consequences of the COVID-19 pandemic on healthcare education in India and the implications
Paras Sharma,Kona Chowdhury,Santosh Kumar,Rohan Bhatt,Tanvi Hirani,Shilpa Duseja,Mainul Haque,Afzalunnessa Binte Lutfor,Ayukafangha Etando,Ranko Škrbić,Moyad Shahwan,Ammar Abdulrahman Jairoun,Brian Godman +12 more
TL;DR: There was a rapid move to online learning among surveyed universities and courses to address lack of familiarity with e-learning approaches with hybrid teaching approaches here to stay.
Journal ArticleDOI
A web-based point prevalence survey of antimicrobial use and quality indicators at Raleigh Fitkin Memorial Hospital in the Kingdom of Eswatini and the implications
TL;DR: Antimicrobial utilization is high at RFM hospital, and identified targets for quality improvement programs include encouraging earlier switching to oral antimicrobials, reducing extended use for surgical prophylaxis and encouraging greater sensitivity testing and documentation stop dates.
Journal ArticleDOI
Evaluating the Performance of a Safe Insulin Supply Chain Using the AHP-TOPSIS Approach
TL;DR: In this paper , a multi-criteria decision-making (MCDM) model that combines Supply Chain Operations Reference (SCOR) metrics, Analytic Hierarchy Process (AHP), and Technique for Order of Preference by Similarity to Ideal Solution (TOPSIS) to develop a model that can prioritize and select the best criteria for maximizing insulin safety and achieving the study objective.
References
More filters
Journal ArticleDOI
Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030
Christian Bommer,Vera Sagalova,Esther Heesemann,Jennifer Manne-Goehler,Jennifer Manne-Goehler,Rifat Atun,Till Bärnighausen,Till Bärnighausen,Justine Davies,Justine Davies,Sebastian Vollmer,Sebastian Vollmer +11 more
TL;DR: The global costs of diabetes and its consequences are large and will substantially increase by 2030 and policy makers need to take urgent action to prepare health and social security systems to mitigate the effects of diabetes.
Journal ArticleDOI
Inequities in access to biologic and synthetic DMARDs across 46 European countries
Polina Putrik,Sofia Ramiro,Tore K Kvien,Tuulikki Sokka,Milena Pavlova,Till Uhlig,Annelies Boonen +6 more
TL;DR: Patients with RA in lower income European countries have less access to bDMARDs and s DMARDs, with particularly striking unaffordability of bDMards in some of these countries, which point to inequities in access to pharmacological treatment for RA in Europe.
Journal ArticleDOI
Diabetes in sub-Saharan Africa: from clinical care to health policy
Rifat Atun,Justine Davies,Justine Davies,Edwin A M Gale,Till Bärnighausen,Till Bärnighausen,David Beran,Andre Pascal Kengne,Naomi S. Levitt,Florence W Mangugu,Moffat J. Nyirenda,Graham D. Ogle,Kaushik Ramaiya,Nelson K. Sewankambo,Eugene Sobngwi,Solomon Tesfaye,John S Yudkin,Sanjay Basu,Christian Bommer,Esther Heesemann,Jennifer Manne-Goehler,Jennifer Manne-Goehler,Iryna Postolovska,Vera Sagalova,Sebastian Vollmer,Sebastian Vollmer,Zulfiqarali G. Abbas,Benjamin Ammon,Mulugeta Terekegn Angamo,Akhila Annamreddi,Ananya Awasthi,Stéphane Besançon,Sudhamayi Bhadriraju,Agnes Binagwaho,Agnes Binagwaho,Philip I. Burgess,Matthew J. Burton,Jeanne Chai,Felix P Chilunga,Portia Chipendo,Anna Conn,Dipesalema Joel,Arielle Wilder Eagan,Crispin Gishoma,Julius Ho,Simcha Jong,Sujay Kakarmath,Yasmin Khan,Ramu Kharel,Ramu Kharel,Michael Anne Kyle,Seitetz C Lee,Amos Lichtman,Carl P Malm,Maimouna Ndour Mbaye,Marie Aimee Muhimpundu,Beatrice Mwagomba,Kibachio Joseph Muiruri Mwangi,Mohit Nair,Simon Pierre Niyonsenga,Benson Njuguna,Obiageli L O Okafor,Oluwakemi Okunade,Paul H. Park,Sonak D. Pastakia,Chelsea Pekny,Ahmed Reja,Charles N. Rotimi,Samuel Rwunganira,David Sando,Gabriela Sarriera,Anshuman Sharma,Assa Traoré Sidibé,Elias S. Siraj,Azhra S Syed,Kristien Van Acker,Mahmoud Werfalli +76 more
Journal ArticleDOI
Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: Results from the International Diabetes Federation Diabetes Atlas, 9th edition.
Christopher Patterson,Suvi Karuranga,Paraskevi Salpea,Pouya Saeedi,Gisela Dahlquist,Gyula Soltész,Graham D. Ogle +6 more
TL;DR: Worldwide estimates of numbers of children and adolescents with type 1 diabetes continue to increase, but prevalence estimates have decreased in the sub-Saharan Africa because allowance has been made for increased mortality in those with diabetes.
Journal ArticleDOI
Ongoing Initiatives to Improve the Quality and Efficiency of Medicine Use within the Public Healthcare System in South Africa; A Preliminary Study.
Johanna C Meyer,Natalie Schellack,Jacobus Stokes,Ruth Lancaster,Helecine Zeeman,Douglas Defty,Brian Godman,Gavin Steel +7 more
TL;DR: Overall, there are an appreciable number of ongoing activities within the public healthcare system in South Africa attempting to ensure and sustain universal healthcare.
Related Papers (5)
Utilisation trend of long-acting insulin analogues including biosimilars across Europe : findings and implications
Brian Godman,Brian Godman,Brian Godman,Magdalene Wladysiuk,Stuart McTaggart,Amanj Kurdi,Amanj Kurdi,Amanj Kurdi,Eleonora Allocati,Mihajlo Jakovljevic,Mihajlo Jakovljevic,Francis Kalemeera,Iris Hoxha,Anna Nachtnebel,Robert Sauermann,Manfred Hinteregger,Vanda Marković-Peković,Biljana Tubić,Guenka Petrova,Konstantin Tachkov,Juraj Slabý,Radka Nejezchlebova,Iva Selke Krulichová,Ott Laius,Gisbert Selke,Irene Langner,András Harsányi,András Inotai,Arianit Jakupi,Svens Henkuzens,Kristina Garuolienė,Jolanta Gulbinovič,Patricia Vella Bonanno,Patricia Vella Bonanno,Jakub Rutkowski,Skule Ingeberg,Øyvind Melien,Ileana Mardare,Jurij Fürst,Sean MacBride-Stewart,Carol Holmes,Caridad Pontes,Corinne Zara,Marta Turu Pedrola,Mikael Hoffmann,Vasileios Kourafalos,Alice Pisana,Rita Banzi,Stephen Campbell,Björn Wettermark +49 more